”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital

The capital increase is intended to complete the clinical and regulatory development of the company’s products in the next 2 years.

Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial

TiGenix announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn’s disease patients

TiGenix submits MAA to EMA for Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients

TiGenix obtains commercial production license for Cx601

Minoryx Therapeutics appoints Dr. Khalid Islam as chairman of the board of directors

Aelix Therapeutics completes Series A funding of €11.5M ($12.7M) for therapeutic HIV vaccine

Ysios Capital leads €11.5 M ($12.7 M) Series A funding round in AELIX Therapeutics.

MedLumics Appoints Cardiovascular Device Expert Tim Lenihan to Board of Directors

TiGenix announces acceptance of Cx601 abstract for presentation at ECCO 2016 Congress

TiGenix files Registration Statement for proposed initial public offering in the United States

Leuven (BELGIUM) – December 22, 2015, 22:30h CET – TiGenix NV (Euronext Brussels: TIG; the “Company”), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its American Depository Shares (“ADSs”) to be listed on the NASDAQ Global Market in the United States.